Q-omics provides the consensus-scored IL36B profile across patient tissues and cancer cell-line models. IL36B expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in KIRP. Among the 18 cancer types available for tumor–normal comparison, IL36B is differentially expressed in 5, with the highest sampling consensus in LUSC. Additionally, IL36B RNA expression shows 9,735 significant gene co-expression associations, with the highest sampling consensus in ESCA. Together, these results highlight KIRP, LUSC, and ESCA as cancer lineages where IL36B shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for IL36B — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes IL36B survival associations across molecular data types. IL36B RNA expression shows survival associations in the most cancer types (23), followed by mutation status (3) and mass-spec protein abundance (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible IL36B RNA expression–survival associations across cancer types. High IL36B expression shows unfavorable associations in KIRP, BLCA, KIRC, UVM and LIHC, but favorable associations in LUSC. The KIRP Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRP as the clearest survival context for IL36B RNA expression.
This table summarizes IL36B tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 5, while mass-spec protein shows differences in 2. The strongest signals are observed in LUSC for RNA and HNSC for protein.
This table ranks reproducible tumor–normal expression differences for IL36B. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. IL36B shows higher tumor expression in LUSC, KIRP, BRCA, KICH and KIRC. The LUSC box plot shows higher IL36B RNA expression in tumor versus normal tissue (log2 FC = +0.700, t-test p < 0.001).
This table shows molecular features associated with IL36B in patient tissues and cancer cell lines. In patient samples, IL36B shows the broadest associations at the RNA and protein expression levels, with ESCA recurring as the lineage with the largest associated feature set. In cancer cell lines, IL36B RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BONE, while CRISPR and shRNA rows add functional-dependency signals in SKIN and KIDNEY.
